Dexmedetomidine Pharmacokinetics During Continuous Renal Replacement Therapy (CRRT)

Last updated: October 23, 2012
Sponsor: Helsinki University Central Hospital
Overall Status: Trial Status Unknown

Phase

2/3

Condition

Kidney Failure

Kidney Disease

Renal Failure

Treatment

N/A

Clinical Study ID

NCT01314209
11102010
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to determine dexmedetomidine pharmacokinetics during continuous renal replacement therapy on critically ill patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18

  • Clinical need for sedation

  • Acute kidney injury requiring renal replacement therapy (according to ICUs standardoperating procedures)

Exclusion

Exclusion Criteria:

  • Severe bradycardia (HR < 50/min)

  • AV conduction block II-III (unless pacemaker installed)

  • Severe hepatic impairment (bilirubin > 101 umol/l)

  • Pregnancy or lactation

  • Age < 18

Study Design

Total Participants: 10
Study Start date:
March 01, 2011
Estimated Completion Date:

Study Description

Dexmedetomidine is a selective alpha-2-adrenergic agonist with sedative properties indicated for sedation of patients in the intensive care setting. ICU patients with acute kidney injury requiring renal replacement therapies frequently have changes in volume status causing alterations in drug pharmacokinetics. Although dexmedetomidine pharmacokinetics have been studied earlier on ICU patients, there is no information on its pharmacokinetics in critically ill patients needing continuous renal replacement therapy.

Connect with a study center

  • Meilahti Hospital, Division of Anaesthesia and Intensive Care Medicine, Department of Surgery, Helsinki University Central Hospital

    Helsinki, 00290
    Finland

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.